Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
October 13, 2016 07:30 ET
|
Esperion Therapeutics, Inc.
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mgBempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and...
Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
January 12, 2016 16:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...